natgillin/translations-raw huggingface dataset:
A pharmaceutical composition comprising the compound according to claim 15, and one or more pharmaceutically acceptable excipients. 
Farmaceutski pripravak, naznačen time što sadrži spoj u skladu bilo kojim od patentnih zahtjeva 1 do 17, kao i jednu ili više farmaceutski prihvatljivih pomoćnih tvari.
The present invention relates to a compound of following formula (I): 
PATENTNI ZAHTJEVI Spoj sljedeće opće formule (I):
or a salt thereof. The compound according to claim 1 or 2, wherein: 
ili njegova sol. Spoj u skladu s patentnim zahtjevom 1 ili 2, naznačen time, da:
In some embodiments, the cancer is a cancer that is difficult to treat. Examples of cancers that are difficult to treat include, but are not limited to, brain cancer (such as glioblastoma), liver cancer, lung cancer, ovarian cancer, pancreatic cancer, and skin cancer (such as melanoma). 
Pripravak za primjenu prema bilo kojem patentnom zahtjevu od 3 do 5, naznačen time, što je rak odabran iz skupine koja se sastoji od raka jetre, raka pluća, raka gušterače, raka mozga, raka želuca, raka jednjaka, raka debelog crijeva te raka glave i vrata.
The use according to claim 1 or 2, wherein the beta blocker is a beta-1 selective beta blocker. 
Uporaba u skladu s patentnim zahtjevom 1 ili 2, naznačena time, da je beta blokator beta-1 selektivni beta blokator.
Solubility of 1-[3-[3-(4-chlorophenyl)propoxy]propyl]-piperidine monohydrochloride, hydrogen oxalate, hydrogen succinate and hydrogen maleate salts was carried out under different conditions: water at room temperature, pH 4.5 and pH 7.4, which pretends to simulate the gastric media and intestinal media respectively. 
Topivost 1-[3-[3-(4-klorfenil)propoksilpropil]-piperidin monoklorida, vodikovog oksalata, vodikovog sukcinata 1 vodikove maleatne soli je izmjerena u različitim uvjetima pri sobnoj temperaturi, pH 4,5 i pH 7,4, što bi trebala biti simulacija želučanog medija odnosno crijevnog medija.
On the contrary, 1-[3-[3-(4-chlorophenyl)propoxy]propyl]-piperidine oxalate is a crystalline substance but its low aqueous solubility (0.025 g/ml at 23°C) also limits its use as a pharmaceutical ingredient. 
Suprotno tome, 1-[3-[3-(4-klorfenil)propoksilpropil]-piperidin oksalat je kristalinična tvar, ali mu slaba topivost u vodi (0,025 g/ml pri 23*C) također ograničava upotrebu kao farmaceutskog sastojka.
The pharmaceutical composition of claim 1, wherein the compound of formula (I) is selected from: 
Farmaceutska kompozicija iz bilo kojeg od patentnih zahtjeva I do 7, gdje spoj sa formulom (I) je odabrano od:
no more than 20%, no more than 15%, no more than 10%, no more than 5%, no more than 3%, no more than 2% or no more than 1% of each of methionine 112 and methionine 148 in said ApoA-I in said population is oxidized; 
oksidirano je ne više od 20%, ne više od 15%, ne više od 10%, ne više od 5%, ne više od 3%, ne više od 2% ili ne više od 1% od svakog metionina 112 i metionina 148 u navedenom ApoA-I u navedenoj populaciji;
On the other hand, Fig. 16 and 17 show a slicing transversely to the fiber direction. 
S druge strane je na slikama 16 i 17 prikazano rezanje kriški popreko na smjer vlakana.
The aqueous pharmaceutical suspension according to claim 7, wherein the hydroxyethylcellulose is, by weight/volume (g/100 mL), about 0.2% to about 0.4%. 
Vodena farmaceutska suspenzija u skladu s patentnim zahtjevom 7, naznačena time što hidroksietilceluloza iznosi, težinski/volumno (g/100 ml), otprilike 0,2 % do otprilike 0,4 %.
The method according to claim 1, comprising about 2 mg to about 8 mg of buprenorphine. 
Pripravak sukladno patentnom zahtjevu 1 sadrži 2 do 8 mg buprenorfina.
The process according to claim 6, wherein said salt is the hydrobromic acid addition salt. 
Postupak prema bilo kojem od zahtjeva 6-11, gdje je navedena sol adicijska sol bromovodične kiseline.
Therefore, additional room for improvement in the art still exists. 
Zbog toga još uvijek ima prostora za poboljšanja u ovom području.
In a second class of this embodiment, the active pharmaceutical ingredient in such compositions comprises about 25% to about 100% by weight of the crystalline monohydrate. 
U jednoj drugoj klasi ove implementacije, aktivan farmaceutski sastojak u takvim pripravcima sadržava oko 25% do oko 100% težinski kristalnog monohidrata.
Skeletal muscular disorder and diseases include, but are not limited to, skeletal muscle fatigue, exercise-induced skeletal muscle fatigue, muscular dystrophy, bladder disorders, and incontinence. 
Uporaba prema patentnom zahtjevu 11, naznačena time što su poremećaji i bolesti skeletnih mišića izabrani iz grupe koju čine zamor skeletnog mišića, zamor skeletnog mišića induciran pojačanom fizičkom aktivnošću, mišićna distrofija, poremećaji bešike 1 inkontinencija.
Toilet basket according to claim 1, wherein the at least one container is in substantially ball-like shape. Toilet basket according to claim 1, wherein the at least one solid preparation is in substantially ball-like shapes. Toilet basket according to claim 1, wherein the one or more inlet openings are in the shape of a slit. 
WC košarica prema jednom od zahtjeva 1 to 4, naznačena time da kruti pripravci (4a, 4b, 4c, 4d) imaju cilindrični oblik ili štapićasti oblik. WC košarica prema jednom od prethodnih zahtjeva, naznačena time da su ulazni otvori (4a, 4b, 4c, 4d) oblikovani na način kao s prorezom.
In particular the compounds of formula (I) and pharmaceutically acceptable salts thereof are of use in the treatment of certain gastrointestinal disorders such as gastroesophageal reflux disorders, functional dyspepsia, irritable bowel syndrome, constipation, intestinal pseudo-obstruction, paralytic ileus following surgery or other manipulation, emesis, gastric stasis or hypomotility caused by various diseases such as diabetes and/or by the administration of other drugs, or in enterally fed patients, Crohn's disease, colitis, cachexia associated with advanced diseases such as cancer and/or the treatment thereof, and other disorders such as incontinence (herein after referred to as the “Disorders of the Invention”). 
Spoj kao što je definirano u bilo kojem od zahtjeva 1 do 7 ili njegova farmaceutski prihvatljiva sol, koji se upotrebljava za liječenje stanja ili poremećaja posredovanih putem receptora GPR38, naznačen time što stanje ili poremećaj su poremećaji gastroezofagealnog refluksa, funkcionalna dispepsija, sindrom iritabilnog crijeva, zatvor, intestinalna pseudo-opstrukcija, paralitički ileus nakon operacije ili druge manipulacije, povraćanje, želučana staza ili hipomotilitet uzrokovan raznim bolestima poput dijabetesa i/ili primjenom drugih lijekova, ili kod enteralno hranjenih pacijenata, Crohnova bolest, kolitis, kaheksija povezana s uznapredovalim bolestima kao što je rak i/ili njegovo liječenje, kaheksija povezana s apetitom/metabolizmom i drugi poremećaji kao što je inkontinencija.
In one embodiment, the recrystallisation (RX) step is a cool acidic recrystallisation (RX-CAR) step. Nitrosylation (NOS) In this step, an N,N-disubstituted-3-optionally substituted aniline, 1, is 4-nitrosylated to give an N,N-disubstituted-3-optionally substituted-4-nitrosyl aniline, 2, as illustrated in the following scheme: 
Diaminofenotiazinski spoj visoke čistoće prema zahtjevu 2 ili 3, naznačen time, da se može dobiti putem postupka sinteze koji obuhvaća sljedeće korake, po redu: nitrozilacija (NOS) u kojoj se N,N-disupstituirani-3-opcionalno supstituirani anilin, 1, 4-nitrozilira kako bi dobio navedeni N,N-disupstituirani-3-opcionalno supstituirani-4-nitrozil-anilin, 2:
C1-6 alkyl which may be substituted with a substituent selected from a halogen atom, a hydroxy, amino, and diC1-6 alkylamino; 
Ci alkila koji može biti supstituiran sa supstituentom izabranim od atoma halogena, hidroksija, amina, i di C,4 alkilamina; C14 alkiltija;
The solid resins may be stored for a longer period before their use in the preparation of foams, they yield foams that are more stable through time and more resistant, but have a higher emission of formaldehyde. 
Čvrste smole se, prije nego što ih upotrijebe kod pripreme pjene,dulje vrijeme sačuvaju, daju pjene, koje su vremenski trajnije 1 črščije, ali ipak uz veću emisiju formaldehida.
The apparatus of claim 1, wherein said tank (20) comprises a radiation shield. 
Uređaj sukladno patentnom zahtjevu 1, pri čemu navedeni spremnik (20) sadrži štit od zračenja.
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-dichloromethylidenebenzonorbornene-5-yl)amide and as component (B) fluopyram. 
Pripravak prema zahtjevu 1, naznačen time da kao komponentu (A) sadrži spoj 3-difluorometil-1-metil-1 H-pirazol-4-karboksilna kiselina (9-diklorometiliden-benzonorbornen-5-il)amid, te kao komponentu (B) spoj koji je izabran između slijedećeg: difenokonazola, propikonazola, kiprokonazola i epoksikonazola.
The compound of claim 16, for use wherein the ectoparasitic infection is with an ectoparasite selected from the group consisting of fleas, ticks, mites, mosquitoes, flies, lice, blowfly and combinations thereof. 
Paraziticidni sastav za uporabu prema zahtjevu 18, naznačen time, da se radi o ektoparazitnim infekcijama koje se prenose ektoparazitima odabranima iz skupine koja se sastoji od buha, krpelji, crva, komaraca, muha, uši, muha zunzara i njihovih kombinacija.
A process for preparing a compound as claimed in any of the claims 1 to 16, said process comprising coupling a compound selected from the group consisting of II-a, II-b, and II-c with a compound III, resulting in derivatives of formula (I) with all substituents R and X having a meaning in accordance with claim 1. 
Postupak za dobivanje spoja prema bilo kojem od zahtjeva 1 do 16, naznačen time da se navedeni postupak sastoji 15 od povezivanja spoja odabranog iz skupine koja se sastoji od IL-a, II-b, i II-c sa spojem III, što rezultira derivatima formule (I) sa svim supstituentima R i X koji imaju značenje u skladu sa zahtjevom 1
Only a reinforcement for the concrete columns 1 is mounted within the recess formed by the adjacent wall elements 2. 
Samo se učvršćenja za betonske stupove 1 postavljaju unutar udubljenja oblikovanih susjednim zidnim elementima 2.
A pharmaceutical composition comprising a compound of the formula (1) and an aqueous buffer, wherein: the composition has a pH of from about 5 to about 6, and 
Farmaceutska kompozicija iz bilo kojeg od patentnih zahtjeva 1 do 6, gdje farmaceutska kompozicija ima pH od oko 4.
The glatiramer acetate and the rasagiline for use according to claim 35, wherein the interval is from 1 to 12 hours. 
Glatiramer acetat i rasagilin za uporabu u skladu s patentnim zahtjevom 35, naznačeni time, da interval jest od 1-12 sati.
The method according to any of the preceding items, wherein the method further comprises the step of applying a balancing layer (4) on the other side of the core (3), before applying heat and pressure, to obtain a balancing layer. 
Metoda u skladu sa bilo kojim od prethodnih patentnih zahtjeva, gdje metoda dalje sadrži korak nanošenja balansirajućeg sloja (4) na drugu stranu jezgre (3), prije primjene topline 1 pritiska, da bi se dobio balansirajući sloj.
to 75% by weight of styrene and/or substituted styrene, and 
2 do 75% po težin stirena i/ili zamijenjeni stiren, i b.
A pharmaceutical composition which is a tablet produced by the method of any one of Claims 1 to 13. The pharmaceutical composition according to claim 14, which comprises tofogliflozin as an active ingredient, lactose hydrate, crystalline cellulose, croscarmellose sodium, and hydrogenated oil and/or magnesium stearate. 
Farmaceutski pripravak naznačen time što je tableta proizvedena postupkom prema bilo kojem od zahtjeva 1 do Farmaceutski pripravak prema zahtjevu 14, naznačen time što o aktivni sastojak sadrži tofogliflozin, laktoza hidrat, kristalnu celulozu, natrijevu kroskarmelozu, te hidrogenirano ulje i/ili magnezijev stearat.
Use of a pharmaceutical composition according to claim 1, for the manufacture of a medicament, optionally adapted for a co-treatment with radiotherapy or radio-immunotherapy, to treat diseases involving cell proliferation, migration or apoptosis of cancer cells, or angiogenesis, in a human or non-human mammalian body. 
Farmaceutski pripravak u skladu s bilo kojim zahtjevom 1 do 10 ili oprema za primjenu farmaceutske kombinacije u skladu sa zahtjevom 15 ili 16, naznačeni time, da se koriste za izradu lijeka, po izboru prilagođenog za zajedničko liječenje s radioterapijom ili radio-imunoterapijom, za uporabu u liječenju oboljenja koja uključuju proliferaciju stanica, migraciju ili apoktozu stanica karcinoma, ili angiogenezu, kod tijela ljudi ili tijela sisavca koji nisu ljudi.
The anti-CLD18A2 antibody of claim 1, wherein the anti-CLD18A2 antibody comprises a heavy chain constant region having an amino acid sequence represented by SEQ ID NO: 150. 
laki lanac koji sadrži aminokiselinsku sekvencu izabranu iz grupe koja se sastoji od SEQ ID NO: 121, 122, 123, 124, 125, 126, 127, 128, 129 i fragmenta iste.
Elastic member 9 is defined by two flexible metal blades 9, which project from the top crosspiece of flat plate 8 and rest on the bottom of the recess or depression 4c formed in the lateral side of longitudinal blade 4. 
Elastični članak 9 je definiran s dvije fleksibilne metalne trake 9 koje strše iz gornjeg poprečnog komada ravne ploče 8 i naslanjaju se na dno udubine ili uleknuća 4c formiranog u bočnoj strani uzdužne lopatice 4.
The monoclonal antibody or antigen binding fragment thereof of claim 1, which binds to three CC chemokines selected from the group consisting of CCL3/MIP-1a,CCL4/MIP-1B, and CCL5/RANTES and which does not bind to CCL2/MCP-1. 
Monoklonsko protutijelo, ili njegov fragment koji veže antigen, u skladu s patentnim zahtjevom 1, naznačeno time, da se veže na tri CC kemokina odabrana iz skupine koju čine CCL3/MIP-10, CCLA/MIP-1f, i CCLS/RANTES i koji se ne vežu na CCL2/MCP-I.
The compound for use according to claim 9, wherein tipifarnib is administered for at least 3 cycles or for at least 6 cycles. 
Spoj za uporabu u skladu s patentnim zahtjevom 9, pri čemu je tipifarnib primjenjivan barem 3 ciklusa ili barem 6 ciklusa.
● laying of roofing or wall covering elements next to one another in a second row, which roofing or wall covering elements partially overlap the roofing or wall covering elements of the first row, and being arranged in such a way that the hook-and-loop connecting elements which are provided on them are aligned substantially and interact with first hook-and-loop connecting elements which are provided on the fastening elements of the first row, in order to fasten the roofing or wall covering elements mechanically in a reversibly releasable manner to the roof or wall substructure . 
* postavljanje krovnih elemenata ili elemenata zidne obloge (1) jednog pored drugoga u drugom redu, navedeni krovni elementi ili elementi zidne obloge djelomično preklapaju krovne elemente ili elemente zidne obloge prvog reda, te su postavljeni na takav način da su kuka-i-petlja spojni elementi (2) koji su na njima predviđeni uglavnom
A method for producing esters expressed by the general formula 1.1, as defined in claim 2, which consists in reaction between the acids expressed by the formula 1.2, as defined in claim 2, and alcohol and thionyl chloride. 
Metoda za proizvodnju estera koji su prikazani općom formulom 1.1, kao što je definirano u patentnom zahtjevu 2, koji se sastoji u reakciji između kiselina koje su prikazane formulom 1.2, kao što je definirano u patentnom zahtjevu 2, i alkohola i tionil klorida.
Some suitable agents are nucleoside HIV reverse transcriptase inhibitors, non-nucleoside HIV reverse transcriptase inhibitors, HIV protease inhibitors, HIV fusion inhibitors, HIV attachment inhibitors, CCR5 inhibitors, CXCR4 inhibitors, HIV budding or maturation inhibitors, and HIV integrase inhibitors. 
Neka pogodna sredstva su nukleozidni inhibitori HIV reverzne transkriptaze, ne-nukleozidni inhibitori HIV reverzne transkriptaze, inhibitori HIV proteaze, inhibitori HIV fuzije, inhibitori HIV vezanja, CCRS5 inhibitori, CXCR4 inhibitori, inhibitori pupanja ili sazrijevanja HIV-a i inhibitori HIV integraze.
Dimethyl fumarate or monomethyl fumarate for use in treating multiple sclerosis, wherein the dimethyl fumarate or monomethyl fumarate is to be administered with a therapeutically effective amount of at least one second immunosuppressive or immunomodulatory compound that does not upregulate the Nrf2 pathway, and wherein the dimethyl fumarate or monomethyl fumarate is to be orally administered to a subject in need of treatment for multiple sclerosis. 
Dimetil fumarat ili monometil fumarat za upotrebu u liječenju multiple skleroze, naznačen time da je dimetil fumarat ili monometil fumarat jedini neuroprotektivni spoj koji se primjenjuje, i pri čemu se dimetil fumarat ili monometil fumarat oralnim putem daje osobi kojoj je potrebno liječenje multiple skleroze u dozi od 480 mg dnevno.
separating said slurry into a yeast-enriched fraction and a PVPP-enriched fraction by means of flotation separation, said flotation separation comprising passing a liquid comprising the slurry through a sedimentation separation vessel in an upward flow and by separately removing a yeast enriched fraction and a PVPP enriched fraction, said PVPP enriched fraction being removed downstream and above of where the yeast enriched fraction is removed; 
razdvajanja navedene kaše na frakciju bogatu kvascem i frakciju bogatu PVPP česticama pomoću flotacijskog separatora, gdje navedena flotacijska separacija podrazumijeva propuštanje tekućine koja sadrži kašu kroz posudu za separaciju sedimentacijom protokom na gore i odvojenim uklanjanjem frakcije bogate kvascem i frakcije bogate PVPP česticama, gdje se navedena frakcija bogata PVPP česticama uklanja nizvodno i iznad mjesta na kojem se uklanja frakcija bogata kvascem;
The belling machine according to claim 6, characterised in that: 
Stroj za oblikovanje u zvono prema zahtjevu 5, naznačen time da:
Within this range an adequate reduction is obtained according to the end product thickness, as well as a very good cooling of each roll to avoid the development of the so-called “fire cracks”. 
Unutar tog raspona dobiva se odgovarajuće smanjenje prema debljini završnog proizvoda, kao i vrlo dobro hlađenje svakog valjka kako bi se izbjeglo stvaranje takozvanih "pucketanja".
The sealing member 8 can also be provided on the region of the top wall 17 of the capsule 1 surrounding the water injector 14 when the water injector 14 is in a position protruding into the interior of the capsule 1. 
Element za nepropusno zatvaranje 8 može također biti postavljen u predjelu gornje stijenke 17 čahure 1, koji predio okružuje injektor za vođu 14, kada je injektor za vodu 14 u takvom položaju da prodire u unutrašnjost čahure 1.
The use according to claim 12 for treatment of arthritis, fibromyalgia, low back pain, post-operative pain, visceral pains like chronic pelvic pain, cystitis, irritable bowel syndrome (IBS), pancreatitis, ischeamic, sciatia, diabetic neuropathy, multiple sclerosis, interstitial cystitis and pain related to interstitial cystitis, HIV neuropathy, asthma, cough and inflammatory bowel disease (IBD), gastro-esophageal reflux disease (GERD), psoriasis, cancer, emesis, urinary incontinence and hyperactive bladder. 
Uporaba prema zahtjevu 12, naznačena time da joj je svrha liječenje artritisa, fibromialgije, križobolje, postoperativne boli, visceralnih bolova poput kronične boli zdjelice, cistitisa, sindroma iritabilnog kolona (IBS), pankreatitisa, ishemije, išijasa, dijabetske neuropatije, multiple skleroze, intersticijalnog cistitisa i boli povezane sa intersticijalnim cistitisom, HIV neuropatije, astme, kašlja i upalne bolesti kolona (IBD), gestro-ezofagealne refluksnc bolesti (GERD), psorijaze, raka, cemeze, urinarne inkontinencije i hipcraktivnog mjehura.
The radio communication terminal apparatus according to claim 1, wherein, the controller, in operation, updates the first accumulation value of the TPC command every time the receiver receives the control information including the TPC command transmitted in a subframe different from said specific subframe. 
Radio komunikacijski terminalni uređaj sukladno zahtjevu 2, naznačen time da je: prva akumulacijska vrijednost, prije nego što se podvrgne navedenom ažuriranju s naredbom TPC, postavljena na nulu nakon navedenog iniciranja.
The method of claim 1, wherein the subject has suffered damage to, or loss of, dorsal root nerve fibers. 
Polipeptid za uporabu kao u zahtjevima 2 ili 3, naznačen time, što je subjekt pretrpio oštećenje živčanih vlakana dorzalnog korjena.
is the side chain residue of an a-amino acid selected from the group consisting of alanine, arginine, asparagine, aspartic acid, Y-carboxyglutamic acid, citrulline, cysteine, glutamic acid, glutamine, glycine, histidine, isoleucine, leucine, lysine, methionine, norleucine, norvaline, ornithine, phenylalanine, serine, threonine, tryptophan, tyrosine, and valine; 
R* je ostatak bočnog lanca o-amino kiseline odabrane od grupe koja se sastoji od alanin, arginin, asparagin, asparaginska kiselina, y-karboksiglutaminska kiselina, citrulin, cistein, glutaminska kiselina, glutamin, glicin, histidin, izoleucin, leucin, lizin, metionin, norleucin, norvalin, ornitin, fenilalanin, serin, treonin, triptofan, tirozin, i valin;
is a phenyl which is substituted with 1 to 3 C1-6 alkoxy; 
Rz jest fenil koji je supstituiran sa 1 do 3 C;4 alkoksija;
Figure 2 shows the results obtained by the taste panel, on a 9-point score, where "1" means extremely poor quality and "9" means excellent quality. 
okus Na Slici 2 prikazani su rezultati ocjenjivanja na ljestvici od 1 do 9, pri čemu «1» znači krajnje lošu kakvoću, a «9» izvrsnu kakvoću.
using the presence or degree of such binding as a measure of the presence of nucleosomes containing the DNA base in the body fluid sample, wherein the DNA base is selected from: uracil, inosine, xanthine, hypoxanthine or a modified base. 
korištenje prisutnosti ili stupnja takvog vezanja kao mjere prisutnosti nukleosoma koji sadrže bazu DNK u uzorku tjelesne tekućine, naznačen time što je baza DNK odabrana od: 5-metilcitozina ili 5-hidroksimetilcitozina.
The balloon filling apparatus of numbered clause 21, wherein the connecting force is provided by an elastic valve configured to automatically seal the balloon if the connecting force is overcome. Numbered clause 23. The apparatus of numbered clause 1, wherein each hole of the plurality of holes at the second end of the housing extends through an outer surface of the housing, the outer surface opposing the opening at the first end of the housing. 
Uređaj u skladu s patentnim zahtjevom 1, naznačen time, da se svaka rupa od većeg broja rupa (26) na drugom kraju (B) kućišta proteže kroz vanjsku površinu kućišta, pri čemu se vanjska površina na drugom kraju kućišta nalazi na suprotnom kraju kućišta od otvora na prvom kraju (A) kućišta (12).
The 31st item relates to a floor panel according to the 29th or 30th item, characterized in that said material part forms a connection between the lock-up body (14) and an attachment portion (50), wherein the lock-up body (14) and the attachment portion (50) consist of material which is less flexible than the aforementioned material part. 
Podni panel prema patentnom zahtjevu 2 ili 3, naznačen time što navedeni dio materijala čini vezu između elementa za blokiranje (14) 1 spojnog dijela (50), pri čemu se element za blokiranje (14) 1 spojni dio (50) sastoje od materijala koji je manje fleksibilan od prethodno navedenog dijela materijala.
Lozenges according to the invention may further comprise a buffer system comprising buffer components. 
Tablete prema izumu mogu dalje sadržavati puferski sustav koji sadrži puferske komponente.